Literature DB >> 24824029

Analysis of BRCA2 loss of heterozygosity in tumor tissue using droplet digital polymerase chain reaction.

Rory L Cochran1, Karen Cravero1, David Chu1, Bracha Erlanger1, Patricia Valda Toro1, Julia A Beaver1, Daniel J Zabransky1, Hong Yuen Wong1, Justin Cidado1, Sarah Croessmann1, Heather Parsons1, Minsoo Kim1, Sarah J Wheelan1, Pedram Argani1, Ben Ho Park1.   

Abstract

Loss-of-heterozygosity (LOH) analysis of archival tumor tissue can aid in determining the clinical significance of BRCA variants. Here we describe an approach for assessing LOH in formalin-fixed, paraffin-embedded (FFPE) tissues using variant-specific probes and droplet digital polymerase chain reaction (ddPCR). We evaluated LOH in 2 related breast cancer patients harboring a rare missense BRCA2 variant of unknown clinical significance (c.6966G>T; M2322I). Conventional PCR followed by Sanger sequencing suggested a change in allelic abundance in the FFPE specimens. However, we found no evidence of LOH as determined by the allelic ratio (wild type-variant) for BRCA2 in both patients' archival tumor specimens and adjacent normal control tissues using ddPCR. In summary, these experiments demonstrate the utility of ddPCR to quickly and accurately assess LOH in archival FFPE tumor tissue.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BRCA2; Droplet digital PCR; Familial breast cancer; LOH; VUS

Mesh:

Substances:

Year:  2014        PMID: 24824029      PMCID: PMC4065621          DOI: 10.1016/j.humpath.2014.03.013

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  15 in total

1.  Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance.

Authors:  Georgia Chenevix-Trench; Sue Healey; Sunil Lakhani; Paul Waring; Margaret Cummings; Ross Brinkworth; Amie M Deffenbaugh; Lynn Anne Burbidge; Dmitry Pruss; Thad Judkins; Tom Scholl; Anna Bekessy; Anna Marsh; Paul Lovelock; Ming Wong; Andrea Tesoriero; Helene Renard; Melissa Southey; John L Hopper; Koulis Yannoukakos; Melissa Brown; Douglas Easton; Sean V Tavtigian; David Goldgar; Amanda B Spurdle
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

2.  Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information.

Authors:  A Osorio; R L Milne; E Honrado; A Barroso; O Diez; R Salazar; M de la Hoya; A Vega; J Benítez
Journal:  Hum Mutat       Date:  2007-05       Impact factor: 4.878

3.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.

Authors:  Timothy R Rebbeck; Henry T Lynch; Susan L Neuhausen; Steven A Narod; Laura Van't Veer; Judy E Garber; Gareth Evans; Claudine Isaacs; Mary B Daly; Ellen Matloff; Olufunmilayo I Olopade; Barbara L Weber
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

4.  Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer.

Authors:  Ana Osorio; Miguel de la Hoya; Raquel Rodríguez-López; Angel Martínez-Ramírez; Alicia Cazorla; Juan José Granizo; Manel Esteller; Carmen Rivas; Trinidad Caldés; Javier Benítez
Journal:  Int J Cancer       Date:  2002-05-10       Impact factor: 7.396

5.  The PIK3CA gene is mutated with high frequency in human breast cancers.

Authors:  Kurtis E Bachman; Pedram Argani; Yardena Samuels; Natalie Silliman; Janine Ptak; Steve Szabo; Hiroyuki Konishi; Bedri Karakas; Brian G Blair; Clarence Lin; Brock A Peters; Victor E Velculescu; Ben Ho Park
Journal:  Cancer Biol Ther       Date:  2004-08-26       Impact factor: 4.742

6.  Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.

Authors:  Andrew D Spearman; Kevin Sweet; Xiao-Ping Zhou; Jane McLennan; Fergus J Couch; Amanda Ewart Toland
Journal:  J Clin Oncol       Date:  2008-09-29       Impact factor: 44.544

7.  A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.

Authors:  Douglas F Easton; Amie M Deffenbaugh; Dmitry Pruss; Cynthia Frye; Richard J Wenstrup; Kristina Allen-Brady; Sean V Tavtigian; Alvaro N A Monteiro; Edwin S Iversen; Fergus J Couch; David E Goldgar
Journal:  Am J Hum Genet       Date:  2007-09-06       Impact factor: 11.025

Review 8.  BRCA1 and BRCA2: 1994 and beyond.

Authors:  Steven A Narod; William D Foulkes
Journal:  Nat Rev Cancer       Date:  2004-09       Impact factor: 60.716

9.  Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

Authors:  Timothy R Rebbeck; Tara Friebel; Henry T Lynch; Susan L Neuhausen; Laura van 't Veer; Judy E Garber; Gareth R Evans; Steven A Narod; Claudine Isaacs; Ellen Matloff; Mary B Daly; Olufunmilayo I Olopade; Barbara L Weber
Journal:  J Clin Oncol       Date:  2004-02-23       Impact factor: 44.544

10.  Fast and accurate short read alignment with Burrows-Wheeler transform.

Authors:  Heng Li; Richard Durbin
Journal:  Bioinformatics       Date:  2009-05-18       Impact factor: 6.937

View more
  3 in total

Review 1.  Current and Emerging Applications of Droplet Digital PCR in Oncology.

Authors:  Susana Olmedillas-López; Mariano García-Arranz; Damián García-Olmo
Journal:  Mol Diagn Ther       Date:  2017-10       Impact factor: 4.074

2.  Quantitative Detection and Genotyping of Helicobacter pylori from Stool using Droplet Digital PCR Reveals Variation in Bacterial Loads that Correlates with cagA Virulence Gene Carriage.

Authors:  Sarah Talarico; Mahboobeh Safaeian; Paula Gonzalez; Allan Hildesheim; Rolando Herrero; Carolina Porras; Bernal Cortes; Ann Larson; Ferric C Fang; Nina R Salama
Journal:  Helicobacter       Date:  2015-12-15       Impact factor: 5.753

3.  TMSB4Y is a candidate tumor suppressor on the Y chromosome and is deleted in male breast cancer.

Authors:  Hong Yuen Wong; Grace M Wang; Sarah Croessmann; Daniel J Zabransky; David Chu; Joseph P Garay; Justin Cidado; Rory L Cochran; Julia A Beaver; Anita Aggarwal; Min-Ling Liu; Pedram Argani; Alan Meeker; Paula J Hurley; Josh Lauring; Ben Ho Park
Journal:  Oncotarget       Date:  2015-12-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.